Squarepoint Ops LLC Has $2.77 Million Stock Holdings in CareDx, Inc. $CDNA

Squarepoint Ops LLC trimmed its position in CareDx, Inc. (NASDAQ:CDNA) by 34.3% during the second quarter, Holdings Channel reports. The institutional investor owned 141,683 shares of the company’s stock after selling 74,120 shares during the quarter. Squarepoint Ops LLC’s holdings in CareDx were worth $2,768,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in CDNA. MCF Advisors LLC lifted its stake in shares of CareDx by 292.9% during the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock valued at $26,000 after acquiring an additional 996 shares during the period. Allworth Financial LP bought a new stake in CareDx during the 2nd quarter worth about $40,000. PNC Financial Services Group Inc. lifted its position in CareDx by 20,200.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company’s stock valued at $79,000 after purchasing an additional 4,444 shares during the period. RiverPark Advisors LLC bought a new position in shares of CareDx in the 2nd quarter valued at about $149,000. Finally, Tower Research Capital LLC TRC grew its position in shares of CareDx by 120.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after buying an additional 4,160 shares during the period.

CareDx Trading Up 0.7%

Shares of CareDx stock opened at $19.49 on Thursday. The stock’s fifty day simple moving average is $16.50 and its 200 day simple moving average is $15.80. The company has a market capitalization of $1.00 billion, a PE ratio of 16.38 and a beta of 2.54. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $25.95.

CareDx (NASDAQ:CDNA) last posted its earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.15. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The firm had revenue of $100.06 million during the quarter, compared to analysts’ expectations of $95.25 million. During the same period in the previous year, the firm earned ($0.14) earnings per share. The company’s revenue was up 20.7% on a year-over-year basis. Analysts predict that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CDNA shares. Wells Fargo & Company increased their price objective on shares of CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday. Wall Street Zen downgraded CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. BTIG Research upped their price objective on CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of CareDx in a report on Monday. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, CareDx has an average rating of “Hold” and an average target price of $26.67.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.